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Abstract
Background: In the absence of treatment options, the WHO emphasizes the identification of effective prevention
strategies as a key element to counteract the dementia epidemic. Regarding the complex nature of dementia, trials
simultaneously targeting multiple risk factors should be particularly effective for prevention. So far, however, only
few such multi-component trials have been launched, but yielding promising results. In Germany, comparable
initiatives are lacking, and translation of these complex interventions into routine care was not yet done. Therefore,
AgeWell.de will be conducted as the first multi-component prevention trial in Germany which is closely linked to
the primary care setting.
Methods: AgeWell.de will be designed as a multi-centric, cluster-randomized controlled multi-component prevention
trial. Participants will be older community-dwelling general practitioner (GP) patients (60–77 years; n = 1,152) with
increased dementia risk according to CAIDE (Cardiovascular Risk Factors, Aging, and Incidence of Dementia) Dementia
Risk Score. Recruitment will take place at 5 study sites across Germany. GP practices will be randomized to either
intervention A (advanced) or B (basic). GPs will be blinded to their respective group assignment, as will be the statistician
conducting the randomization. The multi-component intervention (A) includes nutritional counseling, physical activity,
cognitive training, optimization of medication, management of vascular risk factors, social activity, and, if necessary, further
specific interventions targeting grief and depression. Intervention B includes general health advice on the intervention
components and GP treatment as usual. We hypothesize that over the 2-year follow-up period the intervention group A
will benefit significantly from the intervention program in terms of preserved cognitive function/delayed cognitive decline
(primary outcome), and other relevant (secondary) outcomes (e.g. quality of life, social activities, depressive
symptomatology, cost-effectiveness).
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Discussion: AgeWell.de will be the first multi-component trial targeting risk of cognitive decline in older adults in
Germany. Compared to previous trials, AgeWell.de covers an even broader set of interventions suggested to be beneficial
for the intended outcomes. The findings will add substantial knowledge on modifiable lifestyle factors to prevent or delay
cognitive decline.
Trial registration: German Clinical Trials Register (reference number: DRKS00013555).
Keywords: Prevention, Multi-component intervention, Lifestyle, Cognition, Mental health, Dementia, Primary
care, Cluster-randomized controlled trial, Late life
Background
Relevance
Dementia is not only burdensome for the individuals
affected and their relatives, it is also a major public
health concern [1]. A substantial increase in the ab-
solute number of people affected is to be expected
due to dramatic demographic changes [1, 2]. So far,
most types of dementia, particularly Alzheimer’s de-
mentia (AD) as the most common type (60–70% of
cases; [3]), cannot be cured. Therefore, the identifi-
cation of effective strategies for prevention has been
emphasized as a key element to counteract the de-
mentia epidemic [4, 5].
Numerous vascular and lifestyle factors have been
linked to dementia and AD [6, 7], suggesting that 35%
of current dementia cases could be attributed to nine
modifiable risk factors (midlife hypertension and obes-
ity, diabetes mellitus, depression, physical inactivity,
smoking, low educational attainment, hearing loss, and
social isolation [8–11]. Similar results were found for
Germany, suggesting a tremendous potential for
prevention [10]. Indeed, recent studies indicated trends
towards lower dementia incidence in Western high-in-
come countries, likely being the result of improvements
in such modifiable lifestyle factors [12]. Further modifi-
able risk factors may include the use of anticholinergic
drugs [13] and atrial fibrillation [14]. Previous random-
ized controlled trials (RCTs) on interventions aiming at
preventing cognitive decline, however, mainly focused
on the management of single such risk factors [7]. Re-
garding the complex nature of dementia as well as the
concurrence and interaction of the underlying risk fac-
tors, RCTs simultaneously targeting multiple risk fac-
tors should be more effective [7]. Large international
multi-component trials [15–17] yielded very promising
results in this regard.
The Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER) was
the first large RCT providing evidence that a multi-
component intervention can be effective in improving
or maintaining cognitive functioning in older individ-
uals [5, 16]. Individuals aged 60–77 years (n = 1,200)
with an increased dementia risk were randomly
assigned to receive either a 2-year multi-component
intervention (nutritional counseling, physical activity
enhancement, cognitive training, vascular risk moni-
toring) or regular health advice (control group). The
primary outcome was change in cognition as mea-
sured through a comprehensive neuropsychological
test battery (NTB) [16]. During the 2-year follow-up
period, cognition improved significantly in the inter-
vention group compared to the control group [5].
In Germany, comparable initiatives have been lack-
ing so far. Thus, the AgeWell.de study is designed to
first-time investigate prevention potential for cogni-
tive decline through a multi-component intervention,
with a focus on modifiable risk factors such as, for
example, lifestyle interventions, in older primary care
patients in Germany.
Objectives
The primary objective of AgeWell.de is to evaluate the
effectiveness of a multi-component intervention in pre-
venting or delaying cognitive decline in older adults at
increased risk for dementia, specifically tailored to the
German health care context. To do so, a pragmatic
multi-centric, cluster-randomized controlled prevention
trial will be conducted in primary care. The secondary
objective is to assess effects of the multi-component
intervention regarding (i) mortality, (ii) nursing home
placement, (iii) functioning in everyday activities, (iv)
quality of life, (v) depressive symptoms, (vi) social inclu-
sion, and (vii) the cost-effectiveness of the intervention.
A detailed overview of the study aims and associated hy-
potheses is provided in Fig. 1.
On the one hand, our study will be guided by the
FINGER trial by including the components nutritional
counseling, physical activity enhancement, cognitive
training, and vascular risk monitoring in the 2-year
intervention program. On the other hand, we aim to
additionally include components of social lifestyle and
recommendations on medication overuse and underuse.
Encouraging participants to be socially active should
also be a beneficial component of the intervention as
even in old age an active lifestyle is protective against
dementia [6, 18–20]. Likewise, we will provide specific
recommendations on the medications of the study par-
ticipants to their respective GP, if needed. German
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health claims data suggested that 22–25% of individuals
aged 64 years and older receive at least one prescription
of a potentially inappropriate medication (PIM) drug
within one year [21, 22]. Primary data from a sample of
community-dwelling people with dementia indicate that
22% receive at least one PIM with the highest preva-
lence being antidepressants, benzodiazepines and anal-
getics [23]. PIM constitutes a major public health
concern especially in older age leading, for example, to
an increased risk of adverse drug reactions,
hospitalization, and mortality [24, 25]. Moreover, PIM
is of particular importance as studies strongly suggest
that specific drugs (e.g. with anticholinergic properties)
can also increase the risk for dementia [13, 26, 27]. On
the other hand, medication underuse can modify car-
diovascular and other risks [28] and thus outcomes
relevant for dementia development.
Finally, we will address further known risk factors
for dementia by providing specific interventions in
case of bereavement, grief, and depressive symptoms
[29, 30], if necessary. The broad range of outcomes
will additionally enable the estimation of total benefit
and cost-effectiveness of the intervention suggested to
be more beneficial for the intended outcomes. The
study protocol describes the rationale and the study
design of the AgeWell.de trial in adherence to the
SPIRIT 2013 statement (Standard Protocol Items:
Recommendations for Interventional Trials; [31]).
Methods
Study design
To evaluate the effectiveness of a multi-component inter-
vention in preventing or delaying cognitive decline in older
adults at risk, a multi-centric cluster-randomized controlled
trial with primary care patients will be conducted (Fig. 2).
Inclusion and exclusion criteria
To target individuals at risk for dementia and suitable
for the preventive intervention program, we will include
community-dwelling GP patients who are 60–77 years
old and have an increased CAIDE Dementia Risk Score
(Cardiovascular Risk Factors, Aging, and Incidence of
Dementia; [16, 32]). We will use a CAIDE Dementia
Risk Score ≥ 9 for inclusion. The risk score predicted de-
mentia risk with a sensitivity of 0.77 and a specificity of
0.63, when a cut-off ≥9 was applied [32]. CAIDE is based
on information that is easy to assess (age, education,
gender, blood pressure, body mass index, total choles-
terol, and physical activity). Therefore, case finding of
eligible participants for AgeWell.de can be easily con-
ducted in the GP practices. Moreover, the procedure
could be transferred into daily care later on.
Exclusion criteria are conditions affecting safe engage-
ment in the intervention (malignant disease/fatal illness,
severe clinical depression, symptomatic cardiovascular
disease, revascularization within the previous year) as
judged by the GP; severe loss of vision, hearing, or com-
municative ability/insufficient ability to speak and read
German; severe mobility impairment; concurrent partici-
pation in another intervention trial, and previously diag-
nosed dementia or dementia suspected by the GP.
Interventions
During the 2-year follow-up period, participants of inter-
vention group A (advanced) will receive a systematic
comprehensive multi-component intervention program
(Table 1). All intervention components will be delivered
Fig. 1 Study aims and hypotheses of AgeWell.de
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face-to-face by the study nurses during a visit at the par-
ticipants’ homes. The intervention will include
 advice on healthy nutrition, based on the guidelines
of the German Nutrition Society (DGE)
 exercises for strength, balance and flexibility on two
days per week; aerobic training (3–5 days per week
for 20–30 min) planned individually with the
participant
 cognitive training with tablet computers, using the
cognitive training software “NeuroNation”, three
times per week
 enhancement of social engagement, planned
individually with the participant
 if necessary, feedback on vascular risk factors
(e.g. smoking, medical history) and ways to
reduce the respective risk
 assessment of depressive symptoms and
underlying risk factors (e.g. bereavement, grief ); if
necessary, patients will be encouraged to contact
their GP who will provide adequate support and
care (e.g. referring participants to groups,
psychiatrists, psychotherapists, psychiatric
hospitals); written information on addresses and
helplines which can be contacted in case of grief
and/or depressive symptoms.
 optimization of medication: see Table 1 for a
detailed description.
Participants of intervention group B (basic) will receive
GP treatment as usual (GPTAU) and general health ad-
vice (GHA) related to the components of intervention A.
We hypothesize that the multi-component intervention
program of intervention A will be superior to GPTAU
and GHA (intervention B) regarding trial outcomes.
Outcomes
Primary endpoint
In accordance with previous trials [2, 5, 7], we will
assess change in cognitive performance as the
primary endpoint. Cognitive performance will be
assessed with a neuropsychological test battery cover-
ing the six cognitive domains for diagnosing mild
and/or major neurocognitive disorder according to
DSM-5 (attention, executive function, learning/mem-
ory, language, perceptual-motor abilities, and social
cognition). Composite cognitive z-scores based on the
results from all single tests will be calculated. Single
z-scores will be calculated using baseline mean and
standard deviations and then, for the composite score,
the single z-scores will be averaged.
Secondary endpoints
An overview of secondary endpoints (mortality,
nursing home placement, instrumental activities of
daily living/activities of daily living, quality of life,
depressive symptoms, social inclusion, motivation for
Fig. 2 AgeWell.de study design
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behavior change, cost-effectiveness) is provided in
Fig. 1. Corresponding assessments are detailed in
Table 2. Furthermore, we will assess readiness for
behavior change and explore mediating and moderat-
ing factors for the effectiveness of the intervention.
Sample size
Sample size calculations are based on a composite z-
score of cognitive performance from previous findings
in mild AD [61], i.e., a mean decrease in the composite
z-score of cognitive performance of − 0.21 with a
common SD of 0.5 is assumed in intervention group B
during the two year follow-up period. Accordingly, the
required sample size is estimated to be 475 partici-
pants per group in order to detect a 50% difference in
change in the composite z-score between intervention
groups (2-sided t-test for equal variances; with 5% sig-
nificance level and 90% power). We assume an infla-
tion factor of 1.1 (corresponding to an intra-cluster
correlation coefficient of 0.02 and a cluster size of 6).
In view of the findings from the FINGER trial, we fur-
ther assume a dropout rate of no higher than 10% [5].
Table 1 Components of the AgeWell.de intervention program (intervention group A)
Intervention Component Description
Nutritional counseling - Based on the guidelines of the German Nutrition Society [33] including recommendations e.g. on intake of
cereal products, fruit and vegetables, fish, sugar, salt, and of fluid.
- Anthropometric measurements (height, weight, BMI)
Physical activity enhancement - Combined training program including (i) muscle-strengthening activity, (ii) flexibility activity/balance exercise,
on 2 days/week, and (iii) aerobic activity (3–5 days a week for 20–30 min). Strength and flexibility/balance
training can be conducted at home. Aerobic training will be planned with each participant individually
- Participants will receive a pedometer to record the number of steps walked daily
Cognitive training - Information on cognitive functioning and the impact of cognitive activity/training on cognitive performance
and dementia risk; information on strategies to train cognition in everyday life
- Cognitive training at home on a regular basis (3 times/week, 15 min per session) with tablet computers
(software: NeuroNation; https://www.neuronation.com/)
Optimization of medication - Collection of baseline information (i) from the GP on participants’ medication, diagnoses, and lab values
(creatinine, hemoglobin A1c) and (ii) from the participants on their actual medication
- Electronically supported data evaluation to identify potentially inappropriate medication (e.g. anticholinergics,
using a list based on Gray and coworkers [13], potentially missing drugs (using START criteria A1 to A8; [34]),
contraindicated drug combinations, and contraindications in patients with renal impairment (using databases
from the electronic drug information system AiDKlinik). Discrepancies in the information on medication
collected from the participant and the GP will be identified.
- Reports including recommendations on the medication of a participant will be transmitted to the GP. For
recommended drugs, this will include information on potentially serious drug-drug interactions and on drug
dose adjustment in patients with renal impairment. A procedure is established in case of emergencies, e.g. if an
important drug for a serious condition is not administered by the patient. If a patient reports difficulties with
drug administration (difficulties swallowing tablets or capsules, tablet splitting, subcutaneous injections, use of
inhalers, transdermal patch application, or with the administration of eye drops, nose drops, ear drops, or rectal
or vaginal drug administration), specific information is provided to the patient.
Management of vascular risk
factors
- Assessment of medication and diagnoses, lab values, health parameters, lifestyle factors, blood pressure and
anthropometric measurements (height, weight)
- Information on further vascular risk factors (e.g. smoking, medical history)
- Feedback on vascular risk, importance of reducing the risk, and possible ways of achieving such a reduction
- Nutritional counseling, recommendation of weight loss (if necessary), physical activity enhancement, and
optimization of medication as described above
Enhancement of social
engagement
- Assessment of level of social activity and risk of social isolation
- Information on the importance of an active lifestyle including high social engagement for dementia risk
- Enhancement of social engagement will be planned together with each study participant individually
Bereavement, grief and depressive
symptoms
- Assessment of depressive symptoms and underlying risk factors (e.g. bereavement, grief)
- If necessary, participants will be encouraged to contact their GP and will be provided with adequate support
and care (e.g. referring participants to groups, psychiatrists, psychotherapists, psychiatric hospitals). Additionally,
participants will receive written information on addresses and helplines which can be contacted in case of grief
and/or depressive symptoms.
- If applicable, encouragement to use MoodGym – a scientifically developed and evaluated free web-based
training program to prevent and reduce depressive symptoms (http://www.moodgym-deutschland.de/).
Motivational tasks across all
components
- Personnel continuity regarding the contact person for the participants
- Study nurses will be trained in motivational interviewing techniques and participants will be strongly
encouraged to contact their contact person, whenever necessary
- Birthday/Christmas/holiday cards originally signed by trial authorities/principal investigators
- Participants of intervention A will receive a brochure including recommendations (additional tips and
suggestions each week for an active lifestyle, e.g. recipes, suggestions for physical activity, and information on
healthy ageing) as well as a weekly diary to track their activities in the intervention components.
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Table 2 Instruments used in AgeWell.de
Measures of cognitive performance (primary endpoint)
Construct Instrument
Cognitive performancea • Trail Making Test A and B [35]
• Word List Memory - CERAD
subtest [36–38]
• Verbal Fluency Test - Animals -
CERAD subtest [37–40]
• Constructional Practice – CERAD
subtest [37, 38, 41]
• Reading the Mind in the Eyes Test -
Revised version [42, 43]b
• Montreal Cognitive Assessment
(MoCA; [44]).
Instruments to assess secondary endpoints in AgeWell.de
Construct Instrument
Mortality Information obtained from the GP
or confidant elected by the
participant [self-constructed itemsc]
Nursing home placement Information from the participant or –
if the participant is unavailable or dead –
from the GP or a contact person elected
by the participant
ADL/IADL Barthel Index [45], Amsterdam-IADL
scale [46]a
Quality of life EQ-5D and visual analogue scale
(EQ VAS scale) [47]; WHOQOL-Bref [48],
WHOQOL-Old [49]
Depressive symptomsa Geriatric Depression Scale (GDS; [50, 51])
Social inclusion Lubben Social Network Scale
(LSNS; [52] in combination with
standardized questionnaire on
social activity [self-constructed itemsc]
Cost effectiveness Fragebogen zur Inanspruchnahme
medizinischer und nicht-medizinischer
Versorgungsleistungen im Alter
(FIMA)-Questionnaire for Health-Related
Resource Use in an Elderly Population [53];
unit costs for monetary valuation of
resource use [54]; EQ-5D [47]
Motivation for behavior
change
Stage assessment in the adoption and
maintenance of physical activity and
fruit and vegetable consumption [55–57]
Instruments to assess further information relevant for the AgeWell.de-trial
Construct Instrument
Sociodemographic
information
Standardized questionnaire
(age, sex, educational level/professional
life/activity, living situation/marital status,
socio-economic status)
Subjective cognitive
declinea
Standardized questionnaire on
subjective cognitive decline [58]
Self-reported impairments
and symptoms
Standardized questionnaire on self-reported
impairment in walking, vision, or hearing
[self-constructed itemsc]
Standardized questionnaire on
self-reported anticholinergic
symptoms [self-constructed itemsc]
Anthropometry, blood
pressure
Measurement of height, weight,
blood pressure; calculation of
body-mass-index (BMI)
Table 2 Instruments used in AgeWell.de (Continued)
Measures of cognitive performance (primary endpoint)
Nutrition Standardized questionnaire on food
consumption (food frequency
questionnaire/FFQ [59])
Physical activity I Standardized questionnaire
on physical activity
[self-constructed itemsc]
Bereavement, grief Standardized questionnaire
on bereavement [60]
Medication I (i) Information from the attending
GP on participants’ medication
(“GP-list”) and diagnosesb, lab values
using GP practice records and
(ii) information from participants
on their actual medication
(“brown-bag review”), adherence,
and difficulties with drug administration
using standardized questionnaires
[self-constructed itemsc]
additional vascular risks Standardized questionnaires on additional
vascular risk factors (e.g. smoking,
medical history, familial medical history;
[self-constructed itemsc])
Instruments to assess further information in intervention group A
Construct Instrument
Physical activity II Weekly records on conduct of the
physical activity intervention component,
training, and pedometer results
[self-constructed itemsc]
Cognitive training Weekly records on conduct of
the cognitive training
[self-constructed itemsc]
Medication II Standardized feedback questionnaires on
potential changes in a participant’s
medication or reasons for not following
the recommendations, completed by
the attending GP [self-constructed itemsc]
Social activity Weekly records on social activity, in addition
to the information collected on social
inclusion (see above)
Motivation and readiness
for change
Standardized questionnaire on motivation
and readiness for behavior change [55–57]
Instruments to conduct the process evaluation
Construct Instrument
Success rate of recruitment
and quality of the study
population
Standardized questionnaires filled out
by the GP practice personnel
(number of eligible GP patients,
number of participants and non-participants,
(baseline) characteristics of participants
and non-participants, reasons for
non-participation) [self-constructed itemsc]
Standardized telephone interview on
reasons for leaving the study with
intervention A-participants, if applicable
[self-constructed itemsc]
Quality of the execution of
the intervention, burden
for GP patients and GPs
Standardized interviews with
all intervention A-participants
on adherence to the intervention
components and potential burdens
[self-constructed itemsc]
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Therefore, a total sample size of n = 1,152 individuals
(n = 576 per group) seems sufficient.
Recruitment procedure
To ensure the inclusion of 1,152 patients, recruitment will
take place at five study sites across Germany (Greifswald,
Kiel, Leipzig, and Munich/Halle; Fig. 3). We estimate that
(i) 30% of the GP patients between 60 and 77 years are eli-
gible for the study (according to the FINGER trial, approxi-
mately 40% have the required CAIDE Dementia Risk
Score ≥ 9 [30]; among these another 25% are estimated to
be excluded according to the AgeWell.de exclusion cri-
teria.). Based on previous experiences from other multi-
centric trials [62, 63] and regarding the demanding nature
of this prevention trial, we assume a rather conservative re-
sponse rate of approximately 33%. Thus, every study site
will screen n = 2,880 GP patients to identify n = 864 poten-
tially eligible GP patients (except for Munich/Halle: half
numbers due to shared recruitment between the two study
sites). To ensure these numbers, we suggest a number of
n = 24 GP practices per study site (n = 96 GP practices in
total) as sufficient, leading to a total number of n = 12 pa-
tients that have to be recruited per GP practice. GP prac-
tices will receive monetary incentives for recruitment and
provision of patients’ data.
Randomization
To ensure a balance in sample size across groups over
time, block-randomization of the GP practices will be
used with a targeted assignment ratio of participants to
intervention A vs. B of 1:1. Participating GP practices
(clusters) will be randomized either to intervention A or
B. Randomization will be conducted at the data manage-
ment center at the Institute for General Practice at the
Hannover Medical School, using a randomization list
that is concealed to the recruiting study sites.
Blinding
Whereas blinding of interviewers and study nurses
cannot be realized in AgeWell.de, GPs will be blinded
towards their respective group allocation. Eligible par-
ticipants will receive all necessary information about
the study in an information sheet provided by the GP,
including information on the components of both in-
terventions and on the random assignment of partici-
pants to either intervention A or B. After signing an
informed consent at the GP’s practice, participants will
receive a letter from the study sites with information
on their respective group allocation and on next steps
of the study.
Data collection
Each study center will be recruiting GP practices using
an invitation letter with information on study design and
aims as well as GPs’ duties during the trial. GPs inter-
ested in study participation can reply per fax or tele-
phone. The recruiting study sites will then schedule a
personal appointment at the GP practice to explain the
recruitment procedure and to provide all necessary doc-
uments (informed consent form, patient information,
screening sheets etc.).
Case finding and recruitment will be conducted by the
GP practices. Data of regular GP patients will be
screened by trained practice personnel in association
with the AgeWell.de-study personnel, according to the
Table 2 Instruments used in AgeWell.de (Continued)
Measures of cognitive performance (primary endpoint)
Standardized GP questionnaires
on barriers and facilitators for adherence to
intervention components in the GPs’
view and on own potential burdens
[self-constructed itemsc]
GP general practitioner, ADL Activities of Daily Living, IADL Instrumental
Activities of Daily Living
aInformation should be also used to diagnose DSM-5 Mild and Major
Neurocognitive Disorder/dementia
bThe composite cognitive z-score for the primary endpoint change in
cognitive performance will be calculated based on the test results regarding
these six domains
cQuestionnaires can be obtained from the corresponding author upon request
Fig. 3 AgeWell.de recruitment of participants per study site
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inclusion and exclusion criteria. The GP will then pro-
vide all necessary information about the study to eligible
patients. Patients who are interested in study participa-
tion will sign an informed consent. Contact information
of the patients will be sent to the local recruiting cen-
ters. Next, patients who have consented to participate
will receive a letter from the study personnel, informing
them about their respective group allocation. Home
visits for baseline assessment will be scheduled.
At baseline and at follow-up assessment after 24months,
fully structured interviews will be conducted with all partici-
pants, assessing the primary and secondary endpoints. Other
relevant information assessed include sociodemographic
information, subjective cognitive decline, self-reported im-
pairments and symptoms, anthropometry, blood pressure,
nutrition, physical activity, bereavement/grief, medication,
vascular risks). Moreover, GPs will provide data on partici-
pants’ health characteristics (diagnoses, lab values, medica-
tion) using standardized questionnaires. To conduct the
process evaluation, the success rate of recruitment (number
of eligible GP patients, number of participants and non-par-
ticipants, (baseline) characteristics of participants and non-
participants, reasons for non-participation) will be provided
by the GP practice personnel. Standardized telephone inter-
views on reasons for dropout will be held with intervention
A-participants, if applicable. For participants in intervention
A, additional interim sessions will be scheduled: one face-to-
face assessment after 12months at the participants’ home
and five telephone calls after 2, 4, 8, 16, and 20months, re-
spectively (see Table 3). These fully structured interviews
serve the purpose of monitoring adherence to the interven-
tion and motivation (monitoring & booster sessions). Partic-
ipants in intervention group A will be asked to track their
activities in the intervention components using weekly diar-
ies. To reduce non-response as well as dropout in Age-
Well.de, interviewers will undergo training regarding all
procedures and assessments, including motivational inter-
viewing techniques [64]. Likewise, motivational tasks will
also be carried out by the principal investigators (Table 1).
Data management
Each local recruiting center will enter collected data
via an internet-based electronic data capture system
which complies with the FDA requirements (21 CFR
Part 11) as well as the guidelines for Good Clinical
Practice (GCP). Data will be stored in a central Or-
acle-database. For statistical analyses, data can be
exported via a web-based export-tool into SPSS,
SAS, CDISC ODM, or similar.
The technical infrastructure includes the internet-
based remote data entry system and the central database
server. Data will not be stored locally. For transfers, data
will be secured using 128 bit SSL encryption. Access to
the database and webserver is controlled by two
consecutive firewall systems. Data will only be stored
using a pseudonym generated automatically upon first
entry of a patient’s data into the database. Access to the
electronic data entry system will be provided to mem-
bers of the AgeWell.de study group according to a de-
tailed concept of roles and rights.
Statistical analyses
Preliminary analyses involve three parts. First, data will
be cleaned and checked for inconsistencies by statisti-
cians at the central data management center to ensure
data accuracy and coherence. Second, outcome variables
will be examined to identify potential outliers and lever-
age points. Third, missing data will be inspected and
handled according to patterns of data missingness, e.g.,
by multiple imputation [65].
A dropout analysis will be performed to test whether
complete and incomplete cases differ according to rele-
vant sociodemographic variables, potentially introducing
selection bias.
Descriptive analyses will be carried out to examine differ-
ences in baseline measurements regarding the composite
cognitive z-score (primary endpoint) and secondary end-
points between the two intervention groups. Additionally,
single scores for the six neurocognitive domains will be cal-
culated and analyzed. Suitable balancing techniques, such
as entropy balancing, will be used for baseline measure-
ments to warrant a high degree of comparability between
study groups [66]. In order to analyze changes in primary
and secondary endpoints of the two groups over time
(treatment effect), latent growth curve modeling (LGM)
will be utilized. Group membership (A vs. B) as well as
other time-invariant characteristics will be assessed as pre-
dictors of change in cognitive performance in the models.
Model estimates will be weighted using, for example,
calculated entropy balancing weights to equalize possible
baseline differences in covariates and outcomes. The
models will further be stratified by age and gender to evalu-
ate whether treatment effects on primary and secondary
outcomes differ by subgroups.
Secondary analyses include, among others, investiga-
tion of effects of drug-associated risk factors. Effects
of the intervention in patients with or without such
factors will be analyzed by comparing primary and
secondary endpoints in the respective subgroups.
Plans for stratified analyses by overall cognitive per-
formance as expressed by MoCA scores are effective.
Cost-effectiveness will be analyzed based on both dir-
ect costs and quality-adjusted life-years (QALYs). To
derive direct costs, health care utilization during 24
months follow-up will be valued using specific
German unit costs. Intervention costs will be calcu-
lated using accounting principles. QALYs will be cal-
culated using preference-based utilities as derived
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Table 3 Schedule of enrolment, interventions and assessments in the course of AgeWell.de
1: Telephone interim monitoring and booster sessions 2, 4, 8, 16, and 20 months after baseline-assessment in intervention group A; 2: Face-to-face intervention
visit in intervention group A after 12months; 3: limited assessment of the actual medication via telephone
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from the EQ-5D-5 L. Additionally, incremental cost-ef-
fectiveness ratios (ICER) will be calculated and net benefit
regressions will be conducted to determine the uncer-
tainty of the point estimates of the ICER [67].
Monitoring
Data monitoring
A data monitoring committee will not be established as
the overall risk associated with the trial is considered
low, and therefore, the likelihood for the need to modify
or discontinue the trial is considered insignificant. How-
ever, precautions have been taken to minimize the po-
tential of any harms, as detailed below. Moreover, a
detailed process evaluation will be conducted through-
out the entire trial to produce in-depth insight into the
delivery of the interventions, (i) to prevent drawing in-
appropriate conclusions on the efficacy or effectiveness
of the interventions, and (ii) to formulate recommenda-
tions for future studies [68]. Most importantly, process
evaluation should be used to identify and avoid potential
burdens for study participants and GPs. The process
evaluation will comprise three dimensions:
1) Evaluation of the success rate of recruitment:
Standardized questionnaires filled in by the GP
personnel collecting number of eligible patients,
number of participants and non-participants,
baseline-characteristics of both groups, and reasons
for non-participation. Loss of participants during
the follow-up-period as well as reasons for leaving
the study will be assessed to evaluate attrition rate
as well as barriers and facilitators for staying in the
trial [5].
2) Evaluation of the quality of the execution of the
intervention components: At every face-to-face or
telephone interim session, adherence to the
intervention will be assessed using standardized
questionnaires with intervention A participants in
order to identify potential barriers and facilitators for
adherence to the intervention. Likewise, GPs will be
asked to fill out a standardized questionnaire to
identify potential burdens for participating GPs.
3) Evaluation of the process of data acquisition
regarding completeness and validity:
Documentation of reasons for discontinuing an
assessment before completion as well as the
motivation of the participants and the GPs for
assessment. Number and characteristics of missing
data will be analyzed. Information will be used to
evaluate barriers and facilitators for data collection.
Harms
Trial-related adverse events (AEs) will be assessed without
regard towards a causal relation to the intervention. AEs
will be recorded at each contact with participants after the
baseline assessment. AEs in AgeWell.de include loss experi-
ences and grief, depressive symptoms, severe injuries,
hospitalization, and private or occupational stress reported
by participants. Specific AEs (depressive symptoms; severe
injuries; hospitalization) will be considered serious adverse
events (SAEs) if they result in a life-threatening condition
(immediate risk or death), hospitalization/prolongation
thereof, or any lasting impairment. Occurrence of AEs/
SAEs will be documented in the electronic database after
each contact with participants. In case of a SAE, an auto-
matic case-report form will notify the coordinating study
center at the University of Leipzig, which, in turn, will con-
tact the respective study center. A shared decision will then
be made between the coordinating study center and non-
elective principal investigator (PI) at the respective study
center, including one of the following options: informing
the participants’ GP about the SAE, interruption or discon-
tinuation of trial participation, or none of the above.
Auditing
Auditing will take place in form of reviews of the data
collection across key assessment waves for each re-
cruitment center. Specifically, 2 % of the question-
naires at baseline, at the face-to-face interim
assessment (for intervention group A only), and at fol-
low-up, respectively, will be randomly drawn and
inspected regarding their degree of matching with the
database input. Source data verification will be
performed independently from investigators by the
Hannover Medical School that is the entrusted site
performing all data management tasks throughout the
whole trial.
Protocol amendments
Possible modifications to the protocol will be tracked in
the German Clinical Trials Register (DRKS, registry
number: DRKS00013555).
Dissemination policy
AgeWell.de results will be published in scientific inter-
national, peer-reviewed journals, if possible with open
access. Moreover, results will be presented at national
and international scientific conferences as well as during
seminars for GPs, regional care networks, and public
events for seniors. Furthermore, publication results will
be disseminated to the wider research community via
press releases.
Organizational structure and responsibilities
The Institute for Social Medicine, Occupational
Health and Public Health (ISAP) in Leipzig acts as
the coordinating center in AgeWell.de. This implies
the organization of regular telephone-conferences and
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meetings with all participating centers, the compensa-
tion of all participating GP practices, preparation of
documents needed for the conduct of the trial as well
as reports to the funder of the study. Moreover, the
study center in Leipzig also acts as one of the recruit-
ing centers. As a subcontractor, the Institute for
General Practice at the Hannover Medical School acts
as the responsible study site for the task of data man-
agement, including the setup of the internet-based re-
mote data capture system. The study centers in
Greifswald, Kiel and Munich/Halle act as further
recruiting study sites. Evaluation of cost-effectiveness
of the trial will be conducted by the Department of
Health Economics and Health Service Research at the
University Medical Center Hamburg-Eppendorf. The
intervention component “optimization of medication” will
be realized by the Department of Clinical Pharmacology
and Pharmacoepidemiology at the University Hospital
Heidelberg, including the programming of algorithms to
evaluate electronic data for optimization of medication
and provision of documents for corresponding feedback
to and from the GP.
Discussion
Multi-domain interventions targeting lifestyle factors
have been pointed out as a promising prevention
strategy against dementia in international trials [5].
AgeWell.de will be the first such multi-component
trial in older adults in Germany. We hypothesize
that the multi-component intervention will be
superior to general health advice and GPTAU in
maintaining cognitive functioning in older adults at
risk for dementia (primary hypothesis). Moreover, we
assume beneficial effects in reducing mortality, nurs-
ing home placement, depressive symptoms, and in
maintaining quality of life as well as functioning in
everyday life (secondary hypotheses). Subsequently,
this should also reduce direct health costs.
The AgeWell.de-study will add valuable insights re-
garding the role of modifiable risk and lifestyle factors
to prevent or delay cognitive decline. A specifically
useful asset should be findings from the intervention
components that address potentially inappropriate
medication [13, 26] and depression [8, 9, 69], which,
to our knowledge, have not been examined in com-
parable RCTs so far.
Beyond that, our intervention will possibly also reduce
risk for other diseases such as hypertension, stroke,
cardiovascular disease, overweight etc. by addressing
common risk factors for the respective diseases [2].
Limitations
Participation in our prevention trial is rather demanding
since the intervention components address various lifestyle
factors and require e.g. cognitive training and physical ac-
tivity on several days a week. The follow-up period is longer
than in most previous trials testing single interventions.
Therefore, adherence to the intervention might be lower
compared to trials targeting only single components for a
shorter time period. These factors also raise the chance of
dropping out. We will address these potential problems by
putting a strong focus on continuous motivation of partici-
pants and monitoring of adherence to the intervention, e.g.
by regular telephone contacts and the use of motivational
interviewing techniques. For ethical reasons, general health
advice and feedback on known risk factors for dementia
will also be provided to intervention group B. On these
grounds, estimates of the effects of our intervention should
be considered to be conservative.
Outlook
Since the domains of our multi-component intervention ad-
dress behaviors common in the general population, the
intervention, if effective, will be implemented in real world
settings. Thereby, AgeWell.de could add to targeted and
cost-effective strategies in preventing dementia in older
adults at risk. Most interventions tested (e.g. physical activity
and a wholesome diet) are easily available to the majority of
older adults [70]. Likewise, AgeWell.de addresses lifestyle
factors that are common in general practice. Therefore, even
a moderate decrease in exposure to the targeted lifestyle
factors could lead to a significant reduction in incident
dementia cases on a population level [5, 70]. Concerning the
projected increase in number of dementia cases due to
ageing populations, there is an evident need for effective
prevention strategies. This becomes particularly relevant in
regard to the absence of effective treatment options. To
date, lifestyle interventions might constitute the most cost-
effective and sustainable option for dementia prevention
[71]. Against this background, the results of AgeWell.de will
make a highly relevant contribution to the growing body of
knowledge on modifiable risk factors for dementia.
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